Prevalence and mortality of cancer among HIV-infected inpatients in Beijing, China

BMC Infectious Diseases

Research Article

Fujie Zhang¹  Hongxin Zhao¹  Jun Yang²  Yan Zhao³  Shu Su³  Jiali Wang³  Dennis Wang⁴ 

[1] Beijing Ditan Hospital, Capital Medical University, Beijing, China;Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China;National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China;School of Public Health, Yale University, New Haven, CT, USA;

关键词: HIV;    Cancer;    Concurrence;    Prevalence;    Mortality;    Antiretroviral therapy;    China;   

DOI  :  10.1186/s12879-016-1416-3

 received in 2015-05-01, accepted in 2016-02-05,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundCancer is responsible for elevated HIV-related morbidity and mortality. Research on HIV-infected patients with concurrent cancer is rare in China. The purpose of our study was to investigate the prevalence and risk factors associated with cancer among HIV-infected inpatients in Beijing, and to investigate the mortality and risk factors among HIV-infected inpatients with cancer.MethodsHospital records from a total of 1946 HIV-infected patients were collected from the Beijing Ditan Hospital. The data, from 2008 to 2013, were collected retrospectively. The cancer diagnoses included AIDS-defining cancers (ADC) and non-AIDS defining cancers (NADC). Logistic regression was used to identify risk factors predicting the concurrence of cancer with HIV. Mortality was examined using Kaplan-Meier estimates and Cox proportional hazards models.Results7.7 % (149 cases) of all HIV-infected inpatients had concurrent cancer at their first hospital admission; of those, 33.6 % (50 cases) had ADCs, and 66.4 % (99 cases) had NADCs. The most prevalent NADCs were Hodgkin’s lymphoma, gastrointestinal cancer, liver cancer, and lung cancer. Patients who did not accept antiretroviral therapy (ART) were more likely to suffer from cancer [AOR = 2.07 (1.42–3.01), p = 0.001]. Kaplan-Meier curves indicated that the survival probability of HIV-positive cancer patients was significantly lower than that of HIV-positive cancer-free patients (log-rank test, p < 0.001). For patients diagnosed with cancer, the mortality was also higher among those who did not receive ART [AHR = 2.19 (1.84–2.61), p < 0.001].ConclusionThe prevalence of cancer concurrence among hospitalized HIV-infected patients was 7.7 %. Concurrent cancer also increased mortality among HIV-infected patients. ART was protective against concurrent cancer as well as mortality among HIV-infected cancer patients. These results highlight the importance of promoting cancer screening and early ART initiation among HIV-infected patients.

【 授权许可】

CC BY   
© Yang et al. 2016